These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 32270470)

  • 1. Anxiolytic-like effects of mirogabalin, a novel ligand for α
    Murasawa H; Kobayashi H; Yasuda SI; Saeki K; Domon Y; Arakawa N; Kubota K; Kitano Y
    Pharmacol Rep; 2020 Jun; 72(3):571-579. PubMed ID: 32270470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anxiolytic effects of the novel α
    Murasawa H; Kobayashi H; Saeki K; Kitano Y
    Psychopharmacology (Berl); 2020 Jan; 237(1):189-197. PubMed ID: 31515584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analgesic effects of mirogabalin, a novel ligand for α
    Saeki K; Yasuda SI; Kato M; Kano M; Domon Y; Arakawa N; Kitano Y
    Naunyn Schmiedebergs Arch Pharmacol; 2019 Jun; 392(6):723-728. PubMed ID: 30770951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mirogabalin, a novel ligand for α
    Murasawa H; Pawlak A; Kobayashi H; Saeki K; Yasuda SI; Kitano Y
    Biomed Pharmacother; 2021 Jul; 139():111647. PubMed ID: 33940507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analgesic effects of the novel α₂δ ligand mirogabalin in a rat model of spinal cord injury.
    Domon Y; Kitano Y; Makino M
    Pharmazie; 2018 Nov; 73(11):659-661. PubMed ID: 30396385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding Characteristics and Analgesic Effects of Mirogabalin, a Novel Ligand for the
    Domon Y; Arakawa N; Inoue T; Matsuda F; Takahashi M; Yamamura N; Kai K; Kitano Y
    J Pharmacol Exp Ther; 2018 Jun; 365(3):573-582. PubMed ID: 29563324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mirogabalin activates the descending noradrenergic system by binding to the α
    Oyama M; Watanabe S; Iwai T; Tanabe M
    J Pharmacol Sci; 2021 May; 146(1):33-39. PubMed ID: 33858653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Novel Gabapentinoid Mirogabalin Prevents Upregulation of α2δ-1 Subunit of Voltage-Gated Calcium Channels in Spinal Dorsal Horn in a Rat Model of Spinal Nerve Ligation.
    Domon Y; Kobayashi N; Kubota K; Kitano Y; Ueki H; Shimojo Y; Ishikawa K; Ofune Y
    Drug Res (Stuttg); 2023 Jan; 73(1):54-60. PubMed ID: 36216339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of mirogabalin, a novel ligand for the α₂δ subunit of voltage-gated calcium channels, on N-type calcium channel currents of rat dorsal root ganglion culture neurons.
    Kitano Y; Wakimoto S; Tamura S; Kubota K; Domon Y; Arakawa N; Saito M; Sava B; Buisson B
    Pharmazie; 2019 Mar; 74(3):147-149. PubMed ID: 30961679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological, pharmacodynamics, and clinical profile of mirogabalin besylate (Tarlige
    Kitano Y; Kai K; Yamamura N; Yoshiba S; Kuroha M
    Nihon Yakurigaku Zasshi; 2019; 154(6):352-361. PubMed ID: 31787689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of a new voltage-gated Ca
    Kato J; Inoue T; Yokoyama M; Kuroha M
    Expert Opin Pharmacother; 2021 Dec; 22(17):2311-2322. PubMed ID: 34431423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mirogabalin-A Novel Selective Ligand for the α2δ Calcium Channel Subunit.
    Zajączkowska R; Mika J; Leppert W; Kocot-Kępska M; Malec-Milewska M; Wordliczek J
    Pharmaceuticals (Basel); 2021 Jan; 14(2):. PubMed ID: 33572689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analgesic characteristics of a newly developed α
    Komatsu S; Nakamura S; Nonaka T; Yamada T; Yamamoto T
    Mol Pain; 2021; 17():17448069211052167. PubMed ID: 34823399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxycodone decreases anxiety-like behavior in the elevated plus-maze test in male and female rats.
    Bruijnzeel AW; Behnood-Rod A; Malphurs W; Chellian R; Caudle RM; Febo M; Setlow B; Neubert JK
    Behav Pharmacol; 2022 Sep; 33(6):418-426. PubMed ID: 35947068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mirogabalin as a Novel Gabapentinoid for the Treatment of Chronic Pain Conditions: An Analysis of Current Evidence.
    Chen EY; Beutler SS; Kaye AD; Edinoff AN; Khademi SH; Stoltz AE; Rueb NR; Cornett EM; Suh WJ
    Anesth Pain Med; 2021 Dec; 11(6):e121402. PubMed ID: 35291398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study.
    Tetsunaga T; Tetsunaga T; Nishida K; Misawa H; Takigawa T; Yamane K; Tsuji H; Takei Y; Ozaki T
    J Orthop Surg Res; 2020 May; 15(1):191. PubMed ID: 32456647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mirogabalin: First Global Approval.
    Deeks ED
    Drugs; 2019 Mar; 79(4):463-468. PubMed ID: 30778848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of mirogabalin for the treatment of fibromyalgia: results from three 13-week randomized, double-blind, placebo- and active-controlled, parallel-group studies and a 52-week open-label extension study.
    Arnold LM; Whitaker S; Hsu C; Jacobs D; Merante D
    Curr Med Res Opin; 2019 Oct; 35(10):1825-1835. PubMed ID: 31284771
    [No Abstract]   [Full Text] [Related]  

  • 19. A comparison between Dark Agouti and Sprague-Dawley rats in their behaviour on the elevated plus-maze, open-field apparatus and activity meters, and their response to diazepam.
    Mechan AO; Moran PM; Elliott M; Young AJ; Joseph MH; Green R
    Psychopharmacology (Berl); 2002 Jan; 159(2):188-95. PubMed ID: 11862348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mirogabalin besylate in the treatment of neuropathic pain.
    Burgess J; Javed S; Frank B; Malik RA; Alam U
    Drugs Today (Barc); 2020 Feb; 56(2):135-149. PubMed ID: 32163529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.